Latest Breaking News On - Development therapeutic areas - Page 7 : comparemela.com

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer

Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesCassie hogenkampDavid caouetteKenji yasukawaRoger danseyAhsan arozullahDouglas maffeiAmerican society of clinical oncologyAstellas pharma us incDrug administrationMerck sharp dohme corpSeagen incExchange commissionMerck co incAstellas pharma incInternational agency for research on cancer

Seagen (SGEN) and Astellas Report Positive Topline Results For PADCEV with KEYTRUDA

Seagen (SGEN) and Astellas Report Positive Topline Results For PADCEV with KEYTRUDA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRoger danseyAhsan arozullahAstellas pharma incHead of development therapeutic areasDrug administrationSeagen incImportant safety informationSenior vice presidentDevelopment therapeutic areasChief medical officerBreakthrough therapy

Astellas Submits Fezolinetant New Drug Application to U S FDA

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced a New Drug Application (NDA) for.

United statesKenji yasukawaAhsan arozullahPrzegl menopauzalnyJ public healthDrug administrationHealth qual life outcomesAstellas pharma incHead of development therapeutic areasPrnewswire astellas pharma incNew drug applicationSenior vice presidentDevelopment therapeutic areasFocus area approachEqual lifePenn ovarian aging study

Astellas Submits Fezolinetant New Drug Application to U S FDA

Astellas Submits Fezolinetant New Drug Application to U S FDA
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesKenji yasukawaAhsan arozullahPrzegl menopauzalnyJ public healthDrug administrationHealth qual life outcomesAstellas pharma incHead of development therapeutic areasPrnewswire astellas pharma incNew drug applicationSenior vice presidentDevelopment therapeutic areasFocus area approachEqual lifePenn ovarian aging study

Astellas Highlights Data on Advanced and Rare Cancers during 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will share new research during the 2022 American Society.

United statesKenji yasukawaAhsan arozullahEnfortumab vedotinErhan berrakGlobal medical affairsAmerican society of clinical oncologyEuropean hematology associationAstellas pharma incHead of development therapeutic areasPrnewswire astellas pharma incMedivation incClinical oncologyAnnual meetingSenior vice presidentDevelopment therapeutic areas